PRINCETON, NJ – Dec. 14, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that it has been honored with a 2015 R&D 100 Award in the Software/Services category for Muse® Invent™. This awards program recognizes the 100 most innovative technologies and services of the past year.
Muse Invent allows researchers to create drug candidates with novel structures, scaffolds, or side-chains that meet multiple design objectives. It enables them to create parent structures and then score each generation of offspring until only the strongest drug candidates, those that satisfy all the design criteria, survive. Muse Invent can then describe the synthesis pathway required to create those newly-designed molecules. It is a revolutionary product that successfully bridges the gap between molecular design and synthetic chemistry.
“We are very proud that R&D Magazine chose to recognize Muse Invent’s innovative design with a 2015 R&D 100 Award. It really is an exciting product that enables researchers to design their dream molecules and then quickly determine if they are synthetically feasible. It’s both a creative and a practical tool,” said Brian Masek, a product manager at Certara.
When describing Muse Invent’s potential, R&D Magazine reported: “A successful drug design candidate exploits multiple parameters—potency at the target, selectivity, good ADME properties and minimal toxicity. Certara’s Muse Invent generates new ideas that satisfy these multiple drug design parameters, while empowering chemists to integrate additional computed properties and use them for design optimization.”
About the R&D 100 Awards
Since 1963, the R&D 100 Awards have identified revolutionary technologies newly introduced to the market. Widely recognized as the “Oscars of Invention,” the R&D 100 Awards identify and celebrate the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and high-energy physics spanning industry, academia, and government-sponsored research. For more information, visit http://www.rd100awards.com.
Certara is a global biosimulation technology-enabled drug development company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable superior drug development and regulatory decision-making through biosimulation, thus increasing R&D productivity and commercial value. For more information, visit www.certara.com.
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions